Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus gasseri BNR17

What does the research say about Lactobacillus gasseri BNR17?

4 health outcomes synthesised

Lactobacillus gasseri BNR17 has been studied across 4 health outcomes, with the strongest evidence supporting a moderate-strength, small beneficial effect on reducing waist circumference (3 studies) and abdominal pain (3 studies) in obese adults and adults with functional constipation or IBS. Typical dosing in studies is around 10^10 CFU/day, though not consistently reported across all outcomes.

Strongest evidence:

  • Reduced Waist Circumference (moderate evidence, 3 studies): All 3 studies reported small beneficial effects in obese adults. Dosing was reported in one study as 10^10 CFU/day.
  • Reduced Abdominal Pain (moderate evidence, 3 studies): All 3 studies, all RCTs, found small beneficial effects in adults with functional constipation or irritable bowel syndrome.
  • Reduced Hip Circumference (moderate evidence, 3 studies): 2 studies reported small benefits and 1 found no effect, indicating some inconsistency.

Mixed or weaker evidence:

  • Reduced Body Weight (very low evidence, 3 studies): Only 1 of 3 studies found a statistically significant small benefit; the other 2 found neutral results. The effective dose was 10^10 CFU/day.

Effective dose patterns: The only cross-cutting dose insight is that 10^10 CFU/day appears in studies on waist circumference and body weight, but dosing was not consistently reported across all outcomes, limiting firm dose recommendations.

Population insights: The most commonly studied population across outcomes is obese adults (for waist circumference, hip circumference, and body weight). For abdominal pain, the studied populations include adults with functional constipation or irritable bowel syndrome.

Notable caveats:

  • All evidence bases are small (only 2–3 studies per outcome), so conclusions should be considered preliminary.
  • Publication bias is a concern — null-result studies may be less likely to be published.
  • Dosing was inconsistently reported, limiting dose-specific conclusions for most outcomes.
  • For body weight, most individual studies did not reach statistical significance, so the effect may be smaller than the predominant direction suggests.

Frequently asked

  • What is Lactobacillus gasseri BNR17 good for according to research?
    Research shows moderate evidence for small beneficial effects on reducing waist circumference (3 studies, all beneficial), abdominal pain (3 studies, all beneficial), and hip circumference (2 of 3 studies beneficial). Very low evidence supports a small, inconsistent effect on body weight (1 of 3 studies significant). All studied populations are obese adults or adults with functional constipation/IBS.
  • What dose of Lactobacillus gasseri BNR17 is typically used in studies?
    Doses were not consistently reported across all studies. The only specified effective dose in the evidence is 10^10 CFU/day, which was used in studies on waist circumference and body weight. No other dose ranges are documented in the available syntheses.
  • Who benefits most from Lactobacillus gasseri BNR17?
    The strongest evidence consistently points to obese adults for waist and hip circumference outcomes, and adults with functional constipation or irritable bowel syndrome (IBS-D or IBS with overweight) for abdominal pain. The evidence base is too small to identify specific subgroups (e.g., by age or baseline severity) that benefit more.
  • Are there caveats or limitations in the research on Lactobacillus gasseri BNR17?
    Yes. Every outcome is based on only 2–3 studies, so conclusions are preliminary. Publication bias may inflate positive findings because null results are less likely to be published. Dosing was not consistently reported, and for body weight, most individual studies did not find statistically significant differences between groups.
  • Does Lactobacillus gasseri BNR17 help with reducing waist circumference?
    There is moderate evidence that Lactobacillus gasseri BNR17 has a small beneficial effect on reducing waist circumference in obese adults. All 3 studies reported positive results, and one study used a dose of 10^10 CFU/day. However, the evidence base is small and should be considered preliminary.
  • Does Lactobacillus gasseri BNR17 help with body weight loss?
    The evidence is very low for body weight reduction. Only 1 of 3 studies found a statistically significant small effect, while 2 reported neutral findings. The most-studied dose is 10^10 CFU/day in obese adults aged 19–75 years, but the effect is inconsistent and likely small.
    Back to top